PBE:NYE-Invesco Dynamic Biotechnology & Genome ETF (USD)

ETF | Health |

Last Closing

USD 60.5182

Change

-1.53 (-2.47)%

Market Cap

N/A

Volume

7.79K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-13 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-4.09 (-3.01%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

-1.78 (-2.77%)

USD 2.50B
FXH First Trust Health Care AlphaD..

-1.10 (-1.07%)

USD 0.89B
XHE SPDR® S&P Health Care Equipme..

-0.74 (-0.89%)

USD 0.16B
IDNA iShares Genomics Immunology an..

-0.44 (-2.23%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

-0.84 (-0.85%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

-0.70 (-2.48%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.05 (-0.19%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

-1.44 (-2.59%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.32 (-1.78%)

USD 0.01B

ETFs Containing PBE

WBIR 0.00 % 1.25 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.04% 29% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.04% 29% F 18% F
Trailing 12 Months  
Capital Gain -6.33% 52% F 28% F
Dividend Return 0.01% 6% D- N/A F
Total Return -6.32% 52% F 23% F
Trailing 5 Years  
Capital Gain 8.98% 43% F 35% F
Dividend Return 0.08% 5% F N/A F
Total Return 9.07% 43% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain 1.96% 48% F 44% F
Dividend Return 1.98% 48% F 34% F
Total Return 0.02% 11% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 16.39% 57% F 60% D-
Risk Adjusted Return 12.08% 52% F 31% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.